Brief: Syndax Pharmaceuticals Q3 EPS USD -0.7 Vs. IBES Estimate USD -0.72
03/11/2025 21:01
Nov 03 (Reuters) - Syndax Pharmaceuticals Q3 operating income USD -57.426 million. Q3 operating expenses USD 103.297 million Q3 net income USD -60.715 million vs. IBES estimate USD -61.8 million Q3 cash & investments USD 456.1 million Q3 revenue USD 45.871 million vs. IBES estimate USD 48 million
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million